Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Similar documents
Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Optimizing Clinical Communication in Parkinson s Disease:

Evaluation of Parkinson s Patients and Primary Care Providers

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

10th Medicine Review Course st July Prakash Kumar

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

III./3.1. Movement disorders with akinetic rigid symptoms

Parts of the motor circuits

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Differential Diagnosis of Hypokinetic Movement Disorders

Parkinson s Disease Update

Enhanced Primary Care Pathway: Parkinson s Disease

Treatment of Parkinson s Disease: Present and Future

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

8/28/2017. Behind the Scenes of Parkinson s Disease

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

The PD You Don t See: Cognitive and Non-motor Symptoms

Parkinson s Disease and other related movement disorders a video guide to diagnosis

Alison Charleston 1 st September 2016

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Faculty. Joseph Friedman, MD

Multiple choice questions: ANSWERS

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Evaluation and Management of Parkinson s Disease in the Older Patient

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Clinical Features and Treatment of Parkinson s Disease

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

UNDERSTANDING PARKINSON S DISEASE

Comprehensive Approach to DLB Management

The PD You Don t See: Cognitive and Non-motor Symptoms

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Non-Motor Symptoms of Parkinson s Disease

Moving fast or moving slow: an overview of Movement Disorders

Multiple System Atrophy

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

PARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING. Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH

Parkinson s Disease Current Treatment Options

Update on Parkinson s disease and other Movement Disorders October 2018

Parkinson's Disease KP Update

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Motor Fluctuations in Parkinson s Disease

Non Alzheimer Dementias

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Movement Disorders- Parkinson s Disease. Fahed Saada, MD March 8 th, th Family Medicine Refresher Course St.

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

Headway Victoria Epilepsy and Parkinson s Centre

The Parkinson s Disease Composite Scale

Atypical parkinsonism

Parkinson s Disease. Gillian Sare

Motor symptoms: Tremor: Score (total of four limbs) Absent 0 Symptom not present

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Prior Authorization with Quantity Limit Program Summary

Palladotomy and Pallidal Deep Brain Stimulation

An Approach to Patients with Movement Disorders

Appendix N: Research recommendations

Evolution of a concept: Apraxia/higher level gait disorder. ataxia v. apraxia gait = limb apraxia. low, middle, high gait disturbance levels

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

Dr Barry Snow. Neurologist Auckland District Health Board

Dementia: It s Not Always Alzheimer s

Form D1: Clinician Diagnosis

The Shaking Palsy of 1817

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Basal ganglia motor circuit

Movement Disorders: A Brief Overview

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

Tremor 101. Objectives 9/30/2015. Importance of tremors

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

Over the last 20 years, Deep Brain Stimulation (DBS)

La neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

With Time, The Pathology of PD Spreads Throughout the Brain

Best Medical Treatments for Parkinson s disease

! slow, progressive, permanent loss of neurologic function.

Surgical Management of Parkinson s Disease

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Key Concepts and Issues in Parkinson s Disease in 2016

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Transcription:

Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC

Key Learnings Parkinson Disease (L. Kalia)

Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is a progressive disorder associated with a wide range of symptoms Management of Parkinson disease is not static and is aimed at improving function and quality of life 3

Common Causes Parkinson Disease (L. Kalia) 4

Overview Definition of parkinsonism Differential diagnosis of parkinsonism Etiology and risk factors for PD 5

Parkinsonism Definition A clinical syndrome manifested by: Bradykinesia Rest tremor Rigidity Postural disturbances 6

Parkinsonism Cause Impaired dopamine signalling in basal ganglia 7 From Lanciego et al. Cold Spring Harb 2012

Parkinsonism Cause Impaired dopamine signalling in basal ganglia From www.urmc.rochester.edu 8

Parkinsonism Differential Diagnosis Primary Parkinsonism Parkinson Disease (Sporadic, Familial) Atypical Parkinsonism ( Parkinson Plus Disorders) Dementia with Lewy Bodies (DLB) Progressive Supranuclear Palsy (PSP) Multiple System Atrophy (MSA) Corticobasal Degeneration (CBD) Other Neurodegenerative Disorders (e.g. AD, FTD, CJD) 9

Parkinsonism Differential Diagnosis Secondary Parkinsonism Drugs/Toxins Vascular Infectious Malignancy Other Structural Metabolic Trauma Psychogenic 10

Parkinsonism Differential Diagnosis Primary Parkinsonism Parkinson Disease (Sporadic, Familial) Atypical Parkinsonism ( Parkinson Plus Disorders) Dementia with Lewy Bodies (DLB) Progressive Supranuclear Palsy (PSP) Multiple System Atrophy (MSA) Corticobasal Degeneration (CBD) Other Neurodegenerative Disorders (e.g. AD, FTD, CJD) 11

Parkinson Disease Genetic Causes 12 From Kalia & Lang Lancet 2015

Parkinson Disease Risk Factors 13 From Kalia & Lang Lancet 2015

Assessment Parkinson Disease (L. Kalia) 14

Overview Clinical diagnosis of PD Motor features Non-motor features 15

Clinical Assessment Detailed history and exam aimed at: Confirming features of parkinsonism Identifying any red flags for diagnosis of PD Identifying features that support diagnosis of PD Defining symptoms (motor, non-motor) that negatively impact the patient s function or quality of life 16

Diagnostic Criteria 17 Modified from Kalia & Lang Lancet 2015

Diagnostic Criteria 18 Modified from Kalia & Lang Lancet 2015

Red Flags Early postural instability/falls Early dementia Early prominent dysautonomia Extraocular movement abnormalities Apraxia, Cortical sensory abnormalities Upper motor neuron signs Ataxia Sudden onset Lower body distribution Rapid progression Poor response to L-dopa (1000 mg/d) 19 PSP, MSA LBD, PSP, CBD, AD, CJD MSA PSP, MSA CBD MSA, Vascular, Other MSA Vascular Vascular, NPH Not PD Not PD

Diagnostic Criteria 20 Modified from Kalia & Lang Lancet 2015

Motor Features Bradykinesia Slowness, fatiguing (i.e. reduction in speed and amplitude), or arrests in ongoing movements Slow ADLs, hypomimia, hypophonia, micrographia, reduced hand dexterity, difficulty turning in bed, reduced arm swing, difficulty walking One of the most disabling features of PD 21

Motor Features Rest Tremor Hands > Legs, Face, Other Present or increases with stress or distraction Re-emergent with new posture Present or increases with walking Often impacts patient s self perception and social interactions 22

Motor Features Rigidity Involuntary increase in muscle tone to passive movement Cogwheeling or Lead pipe Mild rigidity can be detected by activation Patients may describe muscle stiffness or pain 23

Motor Features Postural disturbances Flexed posture Postural instability Patients report poor balance, unsteadiness, and falls Can be accompanied by gait dysfunction (e.g. shuffling, freezing) 24

Non-Motor Features Neuropsychiatric features Apathy Depression Anxiety Dementia Hallucinations, Delusions (usually medication induced) Impulse control disorders (usually medication induced) Sleep dysfunction Excessive daytime sleepiness Insomnia RLS/PLMD Sleep apnea REM sleep behaviour disorder Non-REM sleep-related movement disorders 25

Non-Motor Features Dysautonomia Constipation Bladder dysfunction Orthostatic hypotension (exacerbated by meds) Hyperhydrosis Sexual dysfunction Sensory Pain Impaired olfaction Visual dysfunction Other Fatigue Weight loss 26

Management Parkinson Disease (L. Kalia) 27

Overview Treatment approach for PD Challenges in treatment of PD Treatment of motor and non-motor features 28

Disease-Modifying Therapies Current treatments only alleviate symptoms No available therapies to stop or slow disease progression Ongoing clinical trials to identify disease-modifying therapies 29

Treatment Approach Early PD No treatment Non-pharmacological treatment (i.e. exercise) Monotherapy (e.g. MAOBi) Mild/Moderate PD Monotherapy (e.g. L-dopa, Dopamine agonist) Advanced PD Polytherapy Surgical treatment 30

Motor Features 31 Modified from Kalia & Lang Lancet 2015

Initial Treatment No functional impairment Mild symptoms Impact on function/qol Discrete symptoms e.g. Tremor Depression/Anxiety Delay therapy, Clinical trial MAOBi L-dopa, Dopamine agonist Anticholinergic SSRI 32

Response to Treatment Not all motor features respond uniformly to treatment Bradykinesia and rigidity are most responsive Tremor response is variable Postural disturbances are least responsive Treatment of non-motor features often more challenging 33

Treatment Complications Fluctuations (motor, non-motor) Dyskinesia Psychosis (hallucinations, delusions) Impulse control disorders Orthostatic hypotension 34

Motor Complications 35 Modified from Kalia & Lang Lancet 2015

Non-Motor Features 36 Modified from Kalia & Lang Lancet 2015

Surgical Treatments Available surgical treatments: Deep brain stimulation (DBS) Ablative surgery (pallidotomy, thalamotomy) Continuous delivery of L-dopa/carbidopa intestinal gel via PEG/J (DUODOPA ) 37

Surgical Treatments When to consider surgical treatments: Best candidates are age <70 yrs with minimal or no cognitive dysfunction Good response to L-dopa but complicated by significant fluctuations or troublesome dyskinesia Multiple medication trials Refer to specialized centre with multidisciplinary team 38

Implications for Practice Parkinson Disease (L. Kalia) 39

Overview Diagnostic issues in clinical practice Treatment issues in clinical practice Safety issues in clinical practice 40

Diagnostic Issues Not all patients with parkinsonism have PD Early PD can be difficult to differentiate from other causes Neuroimaging (MRI brain) can assist in ruling out other causes No definitive diagnostic test for PD (gold standard: pathology) Diagnosis has implications for treatment and prognosis Accuracy of clinical diagnosis improves with time Re-assess diagnosis and screen for red flags annually (AAN 2009) 41

Treatment Issues 42 Kalia & Lang Lancet 2015

Treatment Issues PD is a progressive disease treatment is not static Goal of treatment is to maximize function and quality of life Assess for fluctuations/dyskinesia at all visits (AAN 2009) Assess for cognitive dysfunction, psychiatric symptoms, sleep disturbances, and autonomic dysfunction annually (AAN 2009) Consider medical/surgical treatment options annually (AAN 2009) Consider rehabilitative therapy options (e.g. PT, OT, SLP) annually (AAN 2009) 43

Safety Issues Provide counselling on safety issues annually (AAN 2009) Medication management Falls and injury prevention Driving Elder abuse 44

Thank you!